Wilbert S Aronow, MD
Wilbert S Aronow, MD
Professor of Medicine
  • : 914-493-5311.

New York Medical College
Westchester, New York
USA

Education

MD 1957 Harvard Medical School

 

Biography

Wilbert S. Aronow MD is Professor of Medicine and Director of Cardiology Research at Westchester Medical Center and New York Medical College, Valhalla, NY USA. He received his MD from Harvard Medical School. He has edited 16 books and is author or co-author of 1,687 papers or book chapters, 550 commentaries, 47 Letters to the Editor, and 1,116 abstracts and is presenter or co-presenter of 1,487 talks at meetings. He has been a member of 177 editorial boards of medical journals, editor-in-chief of 4 journals, co-editor of 3 journals, deputy editor of 1 journal, executive editor of 2 journals, associate editor for 9 journals, and guest editor for 7 other journals. He has also been a member of 4 national guidelines committees.

 

Research Interest

Cardiovascular Diseases

 

Professional Activities:

He has been a member of 4 national guidelines committees including being a coauthor of the 2010 AMDA guidelines for heart failure, co-chair and first author of the 2011 ACC/AHA expert consensus document on hypertension in the elderly, coauthor of the 2015 AHA/ACC/ASH scientific statement on treatment of hypertension in patients with coronary artery disease, and is currently a member of the writing group of the ACC/AHA guideline for the management of patients with hypertension. He was a coauthor of a 2015 position paper from the International Lipid Expert Forum. He was a consultant to the ACP Information and Educational Resource (PIER) on the module of aortic stenosis. He is currently a member of the Board of Directors of the ASPC, and a member of the ACCP Cardiovascular Medicine and Surgery Network Steering Committee.

Dr. Aronow is a Fellow of the ACC, the AHA, the ACP, the ACCP, the AGS (Founding Fellow of Western Section), and the GSA.

 

Honors and Awards

He has received each year from 2001-2015 an outstanding teacher and researcher award from the medical residents and from 2001-2015 from the cardiology fellows at Westchester Medical Center/New York Medical College. He has received awards from the Society of Geriatric Cardiology, the Gerontological Society of America, New York Medical College including the 2014 Chancellor’s Research Award, the F1000 Faculty Member of the Year Award for the Faculty of Cardiovascular Disorders in 2011, 2013, 2014, and 2015, the Walter Bleifeld Memorial Award for distinguished contributions to clinical research from the International Academy of Cardiology in July, 2010, and a Distinguished Fellowship Award from the International Academy of Cardiology in July, 2012.

Publications

  1. Aronow WS. Treating hypertension and prehypertension in older people: when, whom, and how.  Maturitas 2015; 80:31-36.
  2. Jones LG, Sin MK, Hage FG, Kheirbek RE, Morgan CJ, Zile MR, Wu WC, Deedwania P, Fonarow GC, Aronow WS, Prabhu SD, Fletcher RD, Ahmed A, Allman RM. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the veterans affairs vs other hospitals: insights from the BEST trial.  Circulation Heart Failure 2015; 8:17-24.
  3. Pinnamanemi S, Dutta T, Melcer J, Aronow WS. Neurogenic stress cardiomyopathy associated with subarachoid hemorrhage. Future Cardiology 2015; 11:77-87.
  4. Aronow WS. Lessons learned from the TOPCAT trial (editorial). Journal of Clinical and Experimental Cardiology 2015; 6:e138. doi:10.4172/2155-9880.1000e138
  5. Sardar P, Kundu A, Nairooz R, Chatterjee S, Ledley GS, Aronow WS. Health resources variability in the achievement of optimal performance and clinical outcome in ischemic heart disease. Current Cardiology Reports 2015; 17:1 DOI 10.1007/s11886-014-0551-y
  6. Aronow WS. Newer targets and therapies for hypertension and dyslipidemia in diabetics.  Cardiovascular Endocrinology 2015; 4:11-16
  7. Chopra R, Paul L, Manickam R, Aronow WS, Maguire GP. Efficacy and adverse effects of drugs used to treat adult cystic fibrosis  Expert Opinion on Drug Safety  2015; 14: 401-411.
  8. Jain D,  He Zuo-Xiang, Lele V, Aronow WS. Direct myocardial ischemia imaging: a new paradigm in cardiovascular nuclear imaging.  Clinical Cardiology 2015; 38: 124-130..
  9. Aronow WS. Update on management of aneurysms of the abdominal aorta, its branch vessels, and the lower extremities. Angiology Open Access 2015; 4:1http://dx.doi.org/10.4172/2329-9495.1000e109
  10. Aronow WS. Regional differences in heart failure with preserved ejection fraction trials (editorial). Austin Journal of Cardiovascular Disorders 2015; 2 (1):1008
  11. Garg J, Aronow WS, Devabhaktuni S, Ahmad H. Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan. American Journal of Therapeutics 2015; 22:e52-e56
  12. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS,  Athyros V, Djuric DD, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z,  Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Nikolic D, Pella D, Puri R,  M, Rysz J,  Wong ND, Bujnok L, Jones SR, Ray KK, Mikhailidis DP.  Statin intolerance- an attempt at unified definition.  Position paper from International Lipid Expert Forum.  Archives of Medical Science 2015; 11: 1-23.
  13. Aronow WS: Lipid-lowering therapy in the elderly. Archives of Medical Science 2015; 11: 43-56.
  14. Gupta T, Harikrishnan P, Kolte D, Khera S, Subramanian KS, Mujib M, Masud A, Palaniswamy C, Sule S, Jain D, Ahmed A, Lanier GM, Cooper HA, Frishman WH, Bhatt DL, Fonarow GC, Panza JA, Aronow WS. Trends in management and outcomes of ST-elevation myocardial infarction in patients with end stage renal disease in the United States. American Journal of Cardiology 2015; 115: 1033-1041.
  15. Aronow WS. Optimal systolic blood pressure goal in persons aged 60 years and older (editorial). Annals of Clinical and Experimental Hypertension. 2015; 3 (2):1023
  16. Aronow WS. Treatment of intermittent claudication due to peripheral arterial disease (editorial). Angiology: Open Access 2015; 3:1 http://dx.doi.org/10.4172/2329-9495.1000e111
  17. Aronow WS.  Multiple blood pressure medications and mortality among elderly individuals.  JAMA  2015; 313:1362-1363.
  18. Abdelmawgoud A, Brown CJ, Sui X,   Fonarow GC, Kokkinos PF,  Aronow WS, Fletcher RD,  Blair SN, Ahmed A. Relationship of physical activity and healthy eating with mortality and incident heart failure among community-dwelling older adults with normal body mass index. European Society of Cardiology Heart Failure 2015; doi:10.1002/ehf2.12028
  19. Gupta T, Khera S, Kolte D, Aronow WS, Iwai S. Antiarrhythmic properties  of   ranolazine: a review of the current evidence.  International Journal of Cardiology 2015; 187: 66-74.
  20. Nairooz R, Sardar P, Pino M, Aronow WS, Sewani A, Mukherjee D, Mehta JL, Paydak H, Maskoun W. Meta-analysis of risk of stroke and thromboembolism with rivaroxaban versus vitamin K antagonists (VKA) in ablation and cardioversion of atrial fibrillation. International Journal of Cardiology 2015; 187: 345-353.
  21. Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H. Meta-analysis of major bleeding with uninterrupted  warfarin compared to interrupting warfarin and heparin  bridging  in ablation of atrial fibrillation. International Journal of Cardiology 2015; 187: 426-429.
  22. Banach M,  Aronow WS, Serban C, Sahebkar A, Rysz J, Voroneanu L,   Covic A. Lipids, blood pressure, and kidney update 2014. Pharmacological Research 2015; 95-96: 111-125.
  23. Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, Iwai S, Jain D, Sule S, Ahmed A, Cooper HA, Frishman WH, Bhatt DL, Panza JA, Fonarow GC. Regional variation in incidence and outcomes of in-hospital cardiac arrest in the United States.  Circulation 2015; 131: 1415-1425.
  24. Lo IJ, Aronow WS, Tantchou II, Lafaro R, Marav A, Muslim A, Pothula S: Non-typhoidal salmonella abscess in a patient with a large thymoma: a rare presentation and review of literature.  Archives of Medical Science 2015; 11: 453-457.
  25. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB. AHA/ACC/ASH Scientific Statement. Treatment of  hypertension in patients with coronary artery disease:   A Scientific Statement from the  American Heart Association, American College of Cardiology,  and American Society of Hypertension.  Journal of the American College of Cardiology 2015; 65: 1998-2038.
  26. Aronow WS. Blood pressure target goals from guidelines of 2002 to 2014 (editorial). Future Cardiology 2015; 11: 247-250.
  27. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB. AHA/ACC/ASH Scientific Statement. Treatment of  hypertension in patients with coronary artery disease:   A Scientific Statement from the  American Heart Association, American College of Cardiology,  and American Society of Hypertension.  Circulation  2015; 131: e435-e470.
  28. Aggarwal C, Aronow WS. Management of right heart failure. In (ed) Bennington EH, Horizons in World Cardiovascular Research, volume 8, Hauppage, New York, Nova Science Publishers, Inc., 2015 pp 123-136.
  29. Aronow WS. Aortic valve stenosis and aortic regurgitation, pathophysiology and treatment. In Jagadeesh G, Balakumar P, Khin MU (eds). Pathophysiology and Pharmacotherapy of Cardiovascular Disease, Heidelberg, Springer, 2015 pp 1221-1246.
  30. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB. AHA/ACC/ASH Scientific Statement. Treatment of  hypertension in patients with coronary artery disease:   A Scientific Statement from the  American Heart Association, American College of Cardiology,  and American Society of Hypertension.  Hypertension 2015; 65: 1372-1407
  31. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS,  Athyros V, Djuric DD, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z,  Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Nikolic D, Pella D, Puri R,  M, Rysz J,  Wong ND, Bujnok L, Jones SR, Ray KK, Mikhailidis DP.  Statin intolerance- an attempt at unified definition.  Position paper from International Lipid Expert Forum.  Expert Opinion on Drug Safety  2015; 14: 935-955.
  32. Aronow WS. Treatment of lower extremity peripheral arterial disease.  International Heart and Vascular Disease Journal 2015; 3: 3-14
  33. Mujib M, Khanna N, Mazumder NK, Aronow WS, Kolte D, Khera S, Palaniswamy C, Jain D, Lanier GM, Sule S, Ahmed A, Levy W, Prabhu SD, Cooper HA, Panza JA, Gass AL, Fonarow GC. Pre-transplant coagulopathy and in-hospital outcomes among heart transplant recipients: a propensity-matched Nationwide  Inpatient Sample Study.  Clinical Cardiology  2015; 38: 300-308.
  34. Gupta T, Khera S, Kolte D, Aronow WS, Singh T, Pinnamaneni S, Fallon JT, Frishman WH, Gass A. Back from the brink: catastrophic antiphospholipid syndrome.  American Journal of Medicine  2015; 128: 574-577.
  35. Jacobson JT, Iwai S, Aronow WS. Management of ventricular arrhythmias in structural heart disease.  Postgraduate Medicine 2015; 127: 549-559.
  36. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB. AHA/ACC/ASH Scientific Statement. Treatment of  hypertension in patients with coronary artery disease:   A Scientific Statement from the  American Heart Association, American College of Cardiology,  and American Society of Hypertension.  Journal of the American Society of Hypertension  2015; 9: 453-498.
  37. Gupta T, Paul N, Kolte D, Harikrishnan P, Khera S, Aronow WS, Mujib M, Palaniswamy C, Sule S, Jain D, Ahmed A, Cooper HA, Frishman WH, Bhatt DL, Fonarow GC, Panza JA. Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention. Journal of the American Heart Association  2015; 4: e002069 doi: 10.1161/JAHA. 115.002069
  38. Bhatia V, Bajaj NS, Sanam K, Hashim T, Morgan CJ, Prabhu SD, Fonarow GC,  Deedwania P,  Butler J, Carson P, Love TE, Kheirbek R,  Aronow WS, Anker SD, Waagstein F, Fletcher R,  Allman RM, Ahmed A. Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure.  American Journal of Medicine  2015; 128: 715-721.
  39. Aronow WS. Blood pressure goals & targets in the elderly.  Current Treatment Options in Cardiovascular Medicine 2015; 17:33 DOI 10.1007/s11936-015-0394-x
  40. Liu Y, Carrey Z, Aronow WS, Alaie D, Petrillo RL, Frishman WH: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in post-angioplasty restenosis. American Journal of Therapeutics 2015; 22: e107-e114.
  41. Aronow WS. Management of hypertension in the elderly. Current Cardiovascular Risk Reports  July 2015,9:41 DOI 10.1007/s12170-015-0469-y
  42. Kheirbek RE,  Fletcher RD,   Bakitas MA, Fonarow GC, Parvataneni S, Bearden D,  Bailey A, Morgan CJ,  Singh S, Blackman MR, Zile MR, Patel K, Ahmed MB, Tucker RO,  Brown CJ, Love TE,  Aronow WS, Roseman JM, Rich MW,  Allman RM, Ahmed A. . Discharge hospice referral and lower  30-day all-cause readmission in  Medicare beneficiaries hospitalized for heart failure.  Circulation Heart Failure 2015; 8:733-740.
  43. Ahmed AA, Patel K, Nyaku MA, Kheirbek RE,   Bittner V, Fonarow GC, Filippatos GS, Morgan CJ, Aban IB, Mujib M, Desai RV, Allman RM, White M, Deedwania P,  Howard G, Bonow RO, Fletcher RD, Aronow WS,   Ahmed A.  Risk of  heart failure and death  after prolonged smoking cessation: role of amount and duration of prior smoking.    Circulation Heart Failure 2015; 8: 694-701.
  44. Aronow WS.   Review of 2003 to 2015 guidelines on treatment of hypertension in patients with coronary artery disease.  Journal of Hypertension and Management 2015; 1:001.
  45. Aronow WS. Hypertension in patients with coronary artery disease. Heart Health Open Access  2015; http://doc.doi.org/10.14437/2378-7716-2-111
  46. Gupta T, Harikrishnan P, Kolte D, Khera S, Aronow WS, Mujib M, Palaniswamy C, Sule S, Jain D, Ahmed A, Lanier GM, Cooper HA, Frishman WH, Fonarow GC, Panza JA. Outcomes of acute myocardial infarction in patients with hypertrophic cardiomyopathy. American Journal of Medicine  2015; 128: 879-887.
  47. Aronow WS. Drug treatment of hypercholesterolemia. Heart Health Open Access 2015; 2: 1 http://dx.doi.org/10.14437/2378-7716-2-112
  48. Aronow WS. 2015 guidelines on treatment of hypertension in patients with coronary artery disease.  Journal of Cardiology and Therapy 2015; 2: 418-421.
  49. Aronow WS. Mesenteric vascular ischemia (editorial). Angiology Open Access  2015; 3:3 1000e112
  50. Aronow WS. Treatment of hypertension in persons with coronary artery disease: what the guidelines recommend.  Consultant  October,  2015; 55 (10): 2-4.
  51. Nairooz R, Feldman DN, Rochlani Y, Aronow WS, Sardar P, Mukherjee D, Naidu SS, Patel P. Impact of intraprocedural thrombotic events on short-and long-term outcomes following percutaneous coronary intervention. Evidence from a meta-analysis. International Journal of Cardiology 2015; 202:469-476.
  52. Aronow WS. 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Guidelines on Treatment of Hypertension in Patients With Coronary Artery Disease (editorial).  Journal of Hypertension: Open Access  2015; 4: :e113. doi:4172/2167.1095.1000e113
  53. Sharma D, Newman TG, Aronow WS. Lung cancer screening: history, current perspectives, and future directions. Archives of Medical Science 2015; 11: 1033-1043.
  54. Aronow WS. PCSK9 Inhibitors (editorial). Cardiovascular Pharmacology: Open Access  2015; 4:4 http://dx.doi.org/10.4172/2329-6607.1000e128
  55. Aronow WS. Current treatment of hypercholesterolemia. Medical & Clinical Research  2015; http://medclinres.org/archives.php
  56. Khera S, Kolte D, Gupta T, Subramanian KS, Khanna N, Aronow WS, Ahn C, Timmermans RJ, Cooper HA, Fonarow GC, Frishman WH, Panza JA, Bhatt DL. Temporal trends and sex differences in revascularization and outcomes of ST-elevation myocardial infarction in younger adults in the United States. Journal of the American College of Cardiology 2015; 66: 1961-1972.
  57. Aronow WS. Treatment of cardiac hemochromatosis (editorial). Heart Research-Open Journal 2015; 2 (3): e3-e5.
  58. Aronow WS, Frishman WH. Drug treatment of stable coronary artery disease. In: Aronow WS, McClung JA , eds. Translational Research in Coronary Artery Disease: Pathophysiology to Treatment, Waltham, Massachusetts, Elsevier, 2016, pp  167-177.
  59. Jain D, Aronow WS. Noninvasive diagnostic modalities for the evaluation of coronary artery disease. In: Aronow WS, McClung JA , eds. Translational Research in Coronary Artery Disease: Pathophysiology to Treatment, Waltham, Massachusetts, Elsevier, 2016, pp  125-139.
  60. Tariq S, Aggarwal C, Aronow WS. Use of stem cells in ischemic heart disease. In: Aronow WS, McClung JA , eds. Translational Research in Coronary Artery Disease: Pathophysiology to Treatment, Waltham, Massachusetts, Elsevier, 2016, pp  43-47
  61. Jacobson T,  Iwai S, Aronow WS. Current approaches to treatment of ventricular arrhythmias in patients with coronary artery disease.  In: Aronow WS, McClung JA , eds. Translational Research in Coronary Artery Disease: Pathophysiology to Treatment, Waltham, Massachusetts, Elsevier, 2016, pp  141-152
  62. Kolte D, Aronow WS, McClung J. Vasculogenesis and angiogenesis.  In: Aronow WS, McClung JA , eds. Translational Research in Coronary Artery Disease: Pathophysiology to Treatment, Waltham, Massachusetts, Elsevier, 2016, pp  49-65
  63. Aronow WS. Invasive diagnostic assessment of coronary artery disease. In: Aronow WS, McClung JA , eds. Translational Research in Coronary Artery Disease: Pathophysiology to Treatment, Waltham, Massachusetts, Elsevier, 2016, pp  159-165.
  64. Sardar P, Chatterjee S, Pekler G, Pastori LJ, Visco F, Aronow WS. New oral anticoagulants in patients with cancer: current state of evidence. American Journal of Therapeutics 2015; 22: 460-468.
  65. Kundu A, Sardar P, Huston J, Sen P, Chatterjee S, Nairooz R, Ryan JJ, Aronow WS. My patient taking a novel oral anticoagulant with major GI bleeding.  Journal of Atrial Fibrillation 2015; 8:32-37
  66. Aronow WS. Thoracic aortic  aneurysm. Journal of Angiology-Open Access 2015; 3:113.doi:10.4172/2329-9495.1000e.113
  67. Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure.  International Journal of Molecular Science 2015; 16: 29060-29068
  68. Aronow WS. Diagnosis of cardiac hemochromatosis. Heart Health-Open Access 2015; http://dx.doi.org/10.14437/2378-7716-2-115
  69. Aronow WS. White coat hypertension. Insights in Blood  Pressure  2015; 1 No.1:3
  70. Aronow WS. What should the hemoglobin A1c level goal be in diabetics?  International Journal of Diabetology & Vascular Disease Research 2015; 3 (10): 137-139
  71. Harikrishnan P, Gupta T, Palaniswamy C, Kolte D, Khera S, Mujib M, Aronow WS, Ahn C, Sule S, Jain D, Ahmed A, Cooper HA, Jacobson J, Iwai S, Frishman WH, Bhatt DL, Fonarow GC, Panza JA. Temporal trends in incidence and outcomes of complete heart block complicating ST-elevation myocardial infarction.  Journal of the American College of Cardiology EP 2015; 1: 529-538
  72. Banach M, Aronow WS, Serban MC, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2015. Lipids in Health and Disease 2015; 14:167 DOI 10.1186/s12944-0169-0
  73. Aronow WS. Treatment of hypertension in patients with coronary artery disease. International Heart and Vascular Disease Journal 2015; 3 (7): 3-9.
  74. Aronow WS. Lower extremity peripheral arterial disease treatment. SRL Vascular Medicine 2015; 1(1): 001-006.
  75. Nulu S, Aronow WS, Frishman WH. Hypertension in Sub-Saharan Africa: a contextual view of patterns of disease, best management and systems issues. Cardiology in Review  2016; 24: 30-40.
  76. Kolte D, Khera S, Dabhadkar KC, Agarwal S, Aronow WS, Timmermans R, Jain D, Cooper HA, Frishman WH, Menon V, Bhatt DL, Abbott JD, Fonarow GC, Panza JA. Trends ,  in coronary angiography, revascularization, and  outcomes of cardiogenic shock complicating non-ST-elevation myocardial infarction.  American Journal of Cardiology 2016; 117: 1-9.
  77. Aronow WS: Optimal blood pressure goals in patients with hypertension at high risk for cardiovascular events. American Journal of Therapeutics 2016; 23: e218-e223
  78. Sule S, Palaniswamy C, Aronow WS, Ahn C, Peterson SJ, Adapa S, Khera S, Nabors C: Etiology of syncope in patients hospitalized with syncope and predictors of mortality and readmission for syncope at 17-month follow-up: a prospective study. American Journal of Therapeutics 2016;  23: e2-e6
  79. Palaniswamy C, Aronow WS, Agrawal N, Balasubramaniyam N, Lakshmanadoss U: Syncope: approaches to diagnosis and management. American Journal of Therapeutics 2016;  23: e208-e217
  80. Gupta T, Paul N, Palaniswamy C, Balasubramaniyam N, Aronow WS, Kolte D, Khera S, Shah A, Gass A. Sudden cardiac arrest in a patient with apical hypertrophic cardiomyopathy: case report and a brief review of literature.  American Journal of Therapeutics  2016; 23: e276-e282
  81. Sen P, Kundu A, Sardar P, Chatterjee S, Nairooz R, Amin H, Aronow WS. Outcomes after cardioversion in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs): insights from a meta-analysis. American Journal of Cardiovascular Drugs  2016; 16: 33-41.
  82. Aronow WS. Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines.  Expert Opinion on Pharmacotherapy 2016; 17: 205-215
  83. Ahmed MB, Patel K, Fonarow GC, Morgan C, Butler J, Bittner V, Kulczycki A, Kheirbek R, , Aronow WS, Fletcher R, Brown C, Ahmed A. Higher  risk for  incident heart failure and cardiovascular mortality aong community-dwelling octagenarians without pneumococcal vaccination.  European Society of Cardiology Heart Failure 2016;  3:11-17
  84. Aronow WS. Questions not answered by SPRINT (editorial). Journal of Hypertension: Open Access 2016; 5:e116.doi:10.4172/2167-1095.1000e116
  85. Mehta V, Sukhija R, Mehra P, Goyal A, Yusuf J, Mahajan B,  Gupta VK, Tyagi S, Palaniswamy C, Aronow WS. Multimarker risk stratification   approach and  cardiovascular outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. Indian Heart Journal 2016; 68: 57-62.
  86. Aronow WS. Treatment of intermittent claudication due to peripheral arterial disease by medical therapy, supervised exercise, and revascularization (editorial). Angiology Open Access  2015; 3:e111.doi:10.4172/2329-9495.1000e111
  87. Aronow WS. Fractional flow reserve. ARC Journal of Cardiology (AJC)  2016; 2: 7-10
  88. Gupta T, Mujib M, Agarwal P, Prakash P, Garg A, Sharma N, Aronow WS, Nabors C. Association between opioid abuse/dependence and outcomes in hospitalized heart failure patients. American Journal of Therapeutics 2016; 23: e350-e356
  89. Lai HM, Pawar R, Wolf DC, Aronow WS: Impact of cardiovascular risk factors on long-term mortality after liver transplantation. American Journal of Therapeutics 2016; 23: e357-e362
  90. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB. Treatment of hypertension in patients with coronary artery disease. A case-based summary of the 2015 AHA/ACC/ASH scientific statement. Am J Med 2016; 129: 372-378.
  91. Aronow WS. Iron chelation therapy for treatment of cardiac hemochromatosis (editorial). Journal of Clinical and Experimental Cardiology  2016; 7:3 http://dx.doi.org/10.4172/2155-9880.1000e142
  92. Aronow WS. What should the target systolic blood pressure goal be in older diabetics with hypertension? Journal of Integrative Cardiology 2016; 2: 254-255
  93. Anand S, Jayakumar D, Aronow WS, Chandy D. Role of extracorporeal membrane oxygenation in respiratory failure: an overview.  Hospital Practice 2016: 44: 76-85
  94. Valerio MG, Velayati A, Jain D, Aronow WS. Promising new therapies for the treatment of hypercholesterolemia.  Expert Opinion on Biological Therapy 2016; 16: 609-618.
  95. Khanna N, Subramanian KS, Khera S, Aronow WS, Frishman WH. New invasive assessment measures of coronary artery disease severity. Cardiology in Review  2016; 24: 131-135
  96. Gupta T, Kolte D, Khera S,  Harikrishnan P, Mujib M, Aronow WS, Jain D, Ahmed A, Cooper HA, Frishman WH, Bhatt DL, Fonarow GC, Panza JA. Smoker's paradox in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Journal of the American Heart Association 2016; 5(4). pii:e003370.doi:10.1161/JAHA.116.003370.
  97. Paul N, Vuddanda V, Mujib M, Aronow WS. Advances in our understanding of the influence of gender on patient outcomes with peripheral arterial disease co-occurring with diabetes.  Expert Review of Endocrinology & Metabolism 2016; 11: 271-279.
  98. Aronow WS. What should the systolic blood pressure be in older diabetics treated for hypertension (editorial). Cardiovascular Endocrinology 2016; 5: 38-39.
  99. Pierre-Louis B, Rodriques S, Gorospe V, Guddati AK, Aronow WS, Ahn C, Wright M. Clinical factors associated with early readmission among acutely decompensated heart failure patients.  Archives of Medical Science 2016; 12: 538-545
  100. Nairooz R, Ayoub K, Sardar P, Payne J, Almomani A, Pothineni NV, Shailesh F, Aronow WS, Mukherjee D. Uninterrupted  new oral anticoagulants compared to uninterrupted vitamin K antagonists in ablation of atrial fibrillation. A meta-analysis. Canadian Journal of Cardiology 2016; 32:814-823
  101. Velayati A, Valerio MG, Shen M, Tariq S, Lanier GM, Aronow WS. Update on pulmonary arterial hypertension pharmacotherapy.  Postgraduate Medicine  2016; 128: 460-473.
  102. Aronow WS. Non-alcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis (editorial). Future Cardiology 2016; 12: 393-396.
  103. Goyal A, Gupta T, Aronow WS, Panza JA, Cooper HA. Making the case for universal treatment of hypercholesterolemia: a hypothetical comparison with the treatment of   hypertension. American Journal of Cardiology  2016; 118:303-304.
  104. Aronow WS. What should the optimal systolic blood pressure goal be in treating older persons with hypertension? (editorial).  Journal of the American Medical Directors Association 2016; 17: 571-573
  105. Paudel R, Beridze N, Aronow WS, Ahn C, Sanaani A, Agarwal P, Farell K, Jain D, Timmermans R, Cooper HA, Panza JA. Association of chest pain versus dyspnea as presenting symptom for cornary angiography with demographics, coronary anatomy, and 2-year mortality. Archives of Medical Science 2016; 12: 742-746.
  106. Aronow WS. Diagnosis and management of coronary artery disease. In Fillit H, Rockwood K, Young J (eds). Brocklehurst's Textbook of Geriatric Medicine and Gerontology, eighth edition, Philadelphia, Elsevier, 2016 pp 278-287e1-e6
  107. Aronow WS. Valvular heart disease. In Fillit H, Rockwood K, Young J (eds). Brocklehurst's Textbook of Geriatric Medicine and Gerontology, eighth edition, Philadelphia, Elsevier, 2016 pp  307-322e1-e5
  108. Aronow WS. Cardiac arrhythmias. In Fillit H, Rockwood K, Young J (eds). Brocklehurst's Textbook of Geriatric Medicine and Gerontology, eighth edition, Philadelphia, Elsevier, 2016 pp 323-334 e1-e6
  109. Aronow WS. Lower extremity peripheral arterial disease treatment. Gavin Journal of Cardiology and Cardiovascular Disease 2016; 5-11
  110. Iragavarapu C, Gupta T, Chugh SS, Aronow WS, Frishman WH. Type B lactic acidosis associated with venlafaxine overdose. American Journal of Therapeutics 2016; 23: e1082-e1084
  111. Kundu A, Sardar P, Chatterjee S, Owan T,   Aronow WS, Ryan J. Minimizing the risk of bleeding with NOACs in the elderly. Drugs and Aging  2016; 33: 491-500

 

 

 

 

 

Autoimmune Journal Flyer